H7 BioCapital

What H7 BioCapital does

H7 BioCapital is a privately held venture capital firm headquartered in Silicon Valley, California, operating on a three-pillar platform of Venture Investment, BD & Licensing, and Acceleration in the life sciences sector. The firm's venture arm invests in therapeutic companies at IND-enabling or clinical development stages and in medtech companies that are post-revenue or clinically validated; the BD & Licensing pillar facilitates cross-border pharmaceutical partnerships; and the Acceleration pillar runs a 3-month cohort-based healthcare accelerator with Life Science and Medtech tracks, an Angel Syndicate that invests via SPVs from seed to pre-IPO, the H7 Angel Club for individual investors, curated workshops on topics including term sheet negotiation, FDA approval strategy, and IP strategy, and the newly launched H7 Business Development Fellowship (a six-month program, first cohort 2026). The firm monetizes through fund management fees, carried interest on exits, accelerator warrants up to 2% capped at $100K per startup, and event/workshop participation, with revenue not publicly disclosed. H7 serves early-stage healthcare founders, qualified angel investors, and limited partners, with a stated global footprint across North America (USA), Asia (China), and Europe (Germany, France) anchored by the annual JPM Healthcare Week programming (China Night receptions, VC Showcase, Investment Forum) that drew a 10K+ online audience in 2023. The portfolio includes Arthrosi (acquired by Sobi for $1.5B in December 2025) and 20+ other companies across cohorts since 2022.

Name

H7 BioCapital

Legal name

H7 BioCapital

Website

https://h7biocapital.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

H7 BioCapital is a Silicon Valley-based venture capital firm and accelerator investing in life sciences therapeutics and medtech, offering venture funding, BD & licensing support, a 3-month cohort accelerator, and an angel syndicate for healthcare startups and qualified investors.

Ownership category

akta.pro rank

Product category

Venture Capital - Life Sciences

NAICS

Open-End Investment Funds (525910)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life science venture capital
• Healthcare accelerator programs
• Biotech venture investment
• Medtech growth funding
• Angel syndicate investing

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Returns: H7 BioCapital generates returns through equity stakes in portfolio companies, management fees from VC funds, and carried interest from fund performance. They participate in funding rounds of therapeutic and medtech companies.
2. Accelerator Program: The accelerator program charges up to 2% of equity capped at $100K in the format of warrant from selected startups. This provides equity upside potential while the program provides mentorship, workshops, co-working space, and network access.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

H7 BioCapital is a venture capital firm that invests in life science companies, provides business development and licensing support in the pharmaceutical industry, and operates a 3-month cohort-based healthcare accelerator program. The firm targets therapeutic companies at IND-enabling or clinical development stages and post-revenue medtech companies, while also running an angel syndicate that invests through SPVs from seed to pre-IPO stages.

Product overview

H7 BioCapital is a venture capital firm headquartered in Silicon Valley dedicated to life science investment and BD & licensing in the pharmaceutical industry. The company operates a platform-plus-ecosystem model built on three core pillars: Venture Investment, BD & Licensing, and Acceleration. Their venture investment arm targets therapeutic companies in IND-enabling or clinical development and medtech companies post-revenue or supported by clinical validation. Their BD & Licensing services foster partnerships across the healthcare sector. The Acceleration ecosystem includes a 3-month cohort-based Healthcare Accelerator with Life Science and Medtech tracks, the H7 Angel Syndicate (investing through SPVs from seed to pre-IPO), the H7 Business Development Fellowship (a six-month program launching in 2026), H7 Workshops (expert-led sessions on topics from term sheet negotiation to FDA approval), and H7 Conferences (including the annual JPM Investment Forum and VC Showcase events). The company also operates the H7 Angel Club for qualified investors.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Investment
• BD & Licensing
• H7 Healthcare Accelerator
• H7 Angel Syndicate
• H7 Business Development Fellowship
• H7 Angel Club
• H7 Workshops
• H7 Conferences

Quantifiable outcome

• Arthrosi acquisition at up to $1.5 billion valuation

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Plug and PlaycoreGTM or Marketing Partner · 24 October 2023H7 BioCapital partnered with Plug and Play Tech Center to host the 2023 H7 X Plug and Play Healthcare Innovation Summit in Sunnyvale, CA, bringing together healthcare innovators and investors.
• eChinaHealthcoreGTM or Marketing Partner · 12 February 2023H7 BioCapital co-hosted 2023 JPM M7 x eChinaHealth China Night with eChinaHealth during JP Morgan Healthcare Conference week. The partnership involved an international roadshow featuring 13 companies presented simultaneously at venues in China, Germany, and France, reaching 10K+ online audience.
• Dr. Sophie LincoreOthersDr. Sophie Lin joined H7 BioCapital as Partner in September 2025, bringing additional expertise and network to the firm's investment activities.
• Neil J. Littman - Bioverge VenturescoreOthersNeil J. Littman serves as advisor, bringing extensive healthcare VC experience including roles at CIRM managing $3 billion across stem cell and regenerative medicine programs.
• Hongmei Huang, Ph.D. - ClarityNexuscoreOthersHongmei Huang, President of ClarityNexus, serves as advisor to H7 BioCapital's accelerator program and healthcare innovation ecosystem.
• Pegasus Tech VenturesminorOthersDr. Ella Li serves as advisor at Pegasus Tech Ventures, creating cross-connection between the two venture ecosystems.
• Network VCminorOthersDr. Ella Li serves as venture partner at Network VC, expanding network and deal flow between the firms.
• Orrick, Herrington & Sutcliffe LLPcoreImplementation/ SI/ Consulting PartnerScott Iyama, co-chair of Orrick's Life Sciences practice, serves as advisor providing legal expertise for venture financing, M&A, and corporate matters.
• Wilson Sonsini Goodrich & RosaticoreImplementation/ SI/ Consulting PartnerEric Hsu, corporate and securities partner at Wilson Sonsini, serves as advisor specializing in life sciences corporate matters, M&A, and venture capital financing.
• Goodwin Procter LLPcoreImplementation/ SI/ Consulting PartnerCan Cui, Partner at Goodwin Procter, provides IP and technology transaction expertise for cross-border life sciences licensing and collaboration transactions. Goodwin provided venue for demo day events.
• DeloittecoreImplementation/ SI/ Consulting PartnerVivien Wang, Partner at Deloitte specializing in international tax and US inbound investments, serves as advisor providing tax consulting and compliance services.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Plug and Play Tech Center: Large Silicon Valley accelerator and VC platform running cohort-based programs across multiple verticals including health. Co-hosts H7's Healthcare Innovation Summit and competes for similar early-stage healthcare deal flow through its accelerator program.
• ARCH Venture Partners: Established early-stage biotech and medtech VC focused on company formation out of academic research. Comparable in stage and therapeutic focus to H7's venture arm, but with decades of operating history and significantly larger fund sizes.
• Atlas Venture: Early-stage biotech-focused venture firm that builds companies from inception. Similar to H7's therapeutic venture thesis (IND-enabling/clinical-stage biotech), though Atlas operates at substantially larger scale with a longer track record.
• OrbiMed: One of the largest healthcare-dedicated investment firms globally, covering venture, growth, and public equities across therapeutics and medtech. Comparable as a healthcare-focused investor; much larger scale but overlapping therapeutic and medtech investment thesis.
• Boehringer-Ingelheim Venture Fund: Corporate venture arm of Boehringer-Ingelheim investing in early-stage biotech and life sciences, with board representation at US portfolio companies. Comparable as a healthcare/life sciences VC whose senior team (Stephan Pflanz) advises H7, though with materially larger AUM and a strategic-pharma mandate.

Direct peers

• Bioverge Ventures: Silicon Valley-based early-stage VC exclusively dedicated to healthcare startups. Highly comparable to H7: same geography, same stage (seed/early), same therapeutic focus, and Neil Littman serves as an advisor to H7 — a direct overlap in network and thesis.
• Sure Ventures: Silicon Valley early-stage VC investing in startups including healthcare. Comparable in stage and geography to H7; founding partner Gopi Rangan serves as H7 advisor, indicating overlap in deal networks.
• ZGC Capital: Venture firm with US-China cross-border investing focus. Highly comparable because H7's founding partner Dr. Ella Li was formerly CEO of ZGC Capital, and H7 inherits ZGC's US-China bridge thesis — making this a direct peer in cross-border life sciences deal flow.
• Pegasus Tech Ventures: $2B global VC firm with deep technology focus including medical technology, operating accelerator programs. Cross-comparable to H7 given shared advisor relationships (Dr. Ella Li, Bill Reichert) and overlapping accelerator-style model for healthcare and tech startups.

Emerging players

• Good AI Capital: Early-stage AI-focused VC with healthcare exposure. Comparable as a smaller, emerging Silicon Valley VC with an advisor relationship to H7 (Darwin Ling); partial overlap in thesis at the intersection of AI and healthcare investing.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC4y21Mt9oLI1v9gUCYVO11Q
• LinkedInlinkedin.com/company/h7biocapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H7 BioCapital